(Q46023940)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Defining and scoring response to IFN-β in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Nicola De Stefano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Maria Pia Sormani

series ordinal

1

1 reference

http://europepmc.org/abstract/MED/23897407

18 December 2017

language of work or name

English

0 references

publication date

30 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

504-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneurol.2013.146

6 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

The new era of multiple sclerosis therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Current and emerging therapies in multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Interferon beta and glatiramer acetate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Natalizumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Tumefactive multiple sclerosis lesions under fingolimod treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Fingolimod and multiple sclerosis: four cautionary tales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Assessing changes in relapse rates in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Genomics in multiple sclerosis--current state and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Determinants of interferon β efficacy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Clinical consequences of MRI activity in treated multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Clinical Parameters to Predict Response to Interferon in Relapsing Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Regression to the mean in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Refining response to treatment as defined by the Modified Rio Score.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Interleukin 17F level and interferon β response in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.146

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23897407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23897407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23897407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2013.146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23897407%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference